Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Artios Pharma Ltd
Tempus AI
Virginia Commonwealth University
M.D. Anderson Cancer Center
University of Maryland, Baltimore
University of Oklahoma
Columbia University
Fox Chase Cancer Center
Henry Ford Health System
pharmaand GmbH
University of Iowa
Xenetic Biosciences, Inc.
PharmaMar
Ipsen
Pfizer
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Novartis
GOG Foundation
GOG Foundation